Role of cyclooxygenase-2 and 5-lipoxygenase polymorphisms in Alzheimer's disease in a population from Northern Italy: Implication for pharmacogenomics

Journal of Alzheimer's Disease

Volumn 19, Issue 2, 2010, Pages 551-557

  Listì, Florinda ^a   Caruso, Calogero ^a   Lio, Domenico ^a   Colonna Romano, Giuseppina ^a   Chiappelli, Martina ^b   Licastro, Federico ^b   Candore, Giuseppina ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

5 LO; Alzheimer's disease; COX 2; Pharmacogenomics

Indexed keywords

ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 2;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 77049112046     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-1260     Document Type: Article

References (51)

1. Di Bona D, Plaia A,Vasto S, Cavallone L, Lescai F, Franceschi C, Licastro F, Colonna-Romano G, Lio D, Candore G, Caruso C (2008) Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. Brain Res Rev 59, 155-163.
2. Vasto S, Candore G, Duro G, Lio D, Grimaldi MP, Caruso C (2007) Alzheimer's disease and genetics of inflammation: a pharmacogenomic vision. Pharmacogenomics 8, 1735-1745.
3. Vasto S, Candore G, List̀i F, Balistreri CR, Colonna-Romano G, Malavolta M, Lio D, Nuzzo D, Mocchegiani E, Di Bona D, Caruso C (2008) Inflammation, genes and zinc in Alzheimer's disease. Brain Res Rev 58, 96-105.
4. Hoozemans JJ, Rozemuller JM, van Haastert ES, Veerhuis R, Eikelenboom P (2008) Cyclooxygenase-1 and-2 in the different stages of Alzheimer's disease pathology. Curr Pharm Des 14, 1419-1427.
5. Ikonomovic MD, Abrahamson EE, Uz T, Manev H, Dekosky ST (2008) Increased 5-lipoxygenase immunoreactivity in the hippocampus of patients with Alzheimer's disease. J Histochem Cytochem 56, 1065-1073.
6. Masferrer JL, Zweifel BS, Colburn SM, Ornberg RL, Salvemini D, Isakson P, SeibertK(1995) The Role of Cyclooxygenase-2 in Inflammation. Am J Ther 2, 607-610.
7. Ho L, Pieroni C, Winger D, Purohit DP, Aisen PS, Pasinetti GM (1999) Regional distribution of cyclooxygenase-2 in the hippocampal formation in Alzheimer's disease. J Neurosci Res 57, 295-303.
8. Hoozemans JJ, Rozemuller AJ, Janssen I, De Groot CJ, Veerhuis R, Eikelenboom P (2001) Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol (Berl.) 101, 2-8.
9. Oka A, Takashima S (1997) Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons. Neuroreport 8, 1161-1164.
10. Nogawa S, Zhang F, Ross ME, Iadecola C (1997) Cyclooxygenase-2 gene expression in neurons contributes to ischemic brain damage. J Neurosci 17, 2746-2755.
11. Takemiya T, Matsumura K, Yamagata K (2007) Roles of prostaglandin synthesis in excitotoxic brain diseases. Neurochem Int 51, 112-120.
12. Lukiw WJ, Bazan NG (1998) Strong nuclear factor-κB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J Neurosci Res 53, 583-592.
13. D'Acquisto F, Iuvone T, Rombola L, Sautebin L, Di Rosa M, Carnuccio R (1997) Involvement of NF-κBin the regulation of cyclooxygenase-2 protein expression in LPS-stimulated J774 macrophages. FEBS Lett 418, 175-178.
14. Anthony JC, Breitner JC, Zandi PP, Meyer MR, Jurasova I, Norton MC, Stone SV (2000) Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 54, 2066-2071.
15. Etminan M, Gill S, SamiiA(2003) Effect of non-steroidal antiinflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. BMJ 327, 128.
16. Hoozemans JJ, O'Banion MK (2005) The role of COX-1 and COX-2 in Alzheimer's disease pathology and the therapeutic potentials of non-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 4, 307-315.
17. Veld BA, Launer LJ, Breteler MM, Hofman A, Stricker BH (2002) Pharmacologic agents associated with a preventive effect on Alzheimer's disease: a review of the epidemiologic evidence. Epidemiol Rev 24, 248-268.
18. Martin BK, Szekely C, Brandt J, Piantadosi S, Breitner JC, Craft S, Evans D, Green R, Mullan M (2009) Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol 65, 896-905.
19. Bregman N, Karni A, Korczyn AD (2009) Can treatment with nonsteroidal anti-inflammatory drugs protect from dementia? Arch Neurol 66, 539-540.
20. Qin W, Ho L, Pompl PN, Peng Y, Zhao Z, Xiang Z, Robakis NK, Shioi J, Suh J, Pasinetti GM (2003) Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity. J Biol Chem 278, 50970-50977.
21. Qin W, Peng Y, Ksiezak-Reding H, Ho L, Stetka B, Lovati E, Pasinetti GM (2006) Inhibition of cyclooxygenase as potential novel therapeutic strategy in N141l presenilin-2 familial Alzheimer's disease. Mol Psychiatry 11, 172-181.
22. Mirjany M, Ho L, Pasinetti GM (2002) Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J Pharmacol Exp Ther 301, 494-500.
23. Papafili A, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ (2002) Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. Arterioscler Thromb Vasc Biol 22, 1631-1636.
24. Abdullah L, Ait-Ghezala G, Crawford F, Crowell TA, Barker WW, Duara R, Mullan M, (2005) The cyclooxygenase 2-765C promoter allele is a protective factor for Alzheimer's disease. Neurosci Lett 395, 240-243.
25. Ma L, Tang NLS, Zhang YP, Ji L, Tam CWC, Lui VWC, Chiu HF, Lam LC (2008) Association of prostaglandinendoperoxide synthase 2 (PTGS2) polymorphisms and Alzheimer's disease in Chinese. Neurobiol Aging 29, 856-860.
26. Plante H, Picard S, Mancini J, Borgeat P (2006) 5-Lipoxygenase activating protein homodimer in human neutrophils. Evidence for a role in leukotriene synthesis. Biochem J 393, 211-218.
27. Manev H, Manev R (2006) 5-Lipoxygenase (ALOX5) and FLAP(ALOX5AP) gene polymorphisms as factors in vascular pathology and Alzheimer's disease. Med Hypotheses 66, 501-503.
28. Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratic̀o D (2005) Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 58, 623-626.
29. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, Silverman ES, Collins T, Fischer AR, Keith TP, Serino K. Kim SW, De Sanctis GT, Yandava C, Pillari A, Rubin P, Kemp J, Israel E, Busse W, Ledford D, Murray JJ, Segal A, Tinkleman D, Drazen JM (1997) Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 99, 1130-1137.
30. Sayers I, Barton S, Rorke S, Sawyer J, Peng Q, Begh́e B, Ye S, Keith T, Clough JB, Holloway JW, Sampson AP, Holgate ST (2003) Promoter polymorphism in the 5-lipoxygenase (ALOX5) and 5-lipoxygenase-activating protein (ALOX5AP) genes and asthma susceptibility in a Caucasian population. Clin Exp Allergy 33, 1103-1110.
31. Dwyer JH, Allayee H, Dwyer KM, Fan J,Wu H, Mar R, Lusis AJ, Mehrabian M (2004) Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med 350, 29-37.
32. List̀i F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CR, Vasto S, Scafidi V, Caruso C, Candore G (2008) Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des 14, 2678-2685.
33. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) " Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Service Task Force on Alzheimer's Disease". Neurology 34, 939-944.
34. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders: DSM-III-R, 3rd revised ed. Washington (DC), American Psychiatric Association.
35. Miller SA, Dykes DD, Polesky HF (1998) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16, 1215.
36. Licastro F, Porcellini E, Caruso C, Lio D, Corder EH (2007) Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation. Neurobiol Aging 28, 1637-1643.
37. Perneger TV (1998) What's wrong with Bonferroni adjustments? Br Med J 316, 1236-1238.
38. Powell EE, Edwards-Smith CJ, Hay JL, Clouston AD, Crawford DH, Shorthouse C, Purdie DM, Jonsson JR (2000) Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 31, 828-833.
39. Dupont WD, Plummer WD Jr. (1990) Power and sample size calculations. A review and a computer program. Control Clin. Trials 11, 116-128.
40. Akiyama S, Barger S, Barnum B, Bradt J, Bauer GM, Cole NR, Cooper NR, Eikelenboom P, Emmerling M, Fiebich B, Finch CE, Frautschy S, GriffinWST, Hampel H, Hull M, Landreth G, Lue LF, Mrak R, Mackenzie IR, McGreer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyama I, Van Muiswinkel FL. Veerhuis R, Walker D, Webster S, Wegrzynia G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21, 383-1321
41. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39, 17-23.
42. Ulrich CM, Whitton J, Yu JH, Sibert J, Sparks R, Potter JD, Bigler J (2005) PTGS2 (COX-2)-765G > C promoter variant reduces risk of colorectal adenoma among nonusers of nonsteroidal anti-inflammatory drugs. Cancer Epidemiol Biomarkers Prev 14, 616-619.
43. List̀i F, Caruso M, Incalcaterra E, Hoffmann E, Caimi G, Balistreri CR, Vasto S, Scafidi V, Caruso C, Candore G (2008) Pro-inflammatory gene variants in myocardial infarction and longevity: implications for pharmacogenomics. Curr Pharm Des 14, 2678-2685
44. Vasto S, Carruba G, Lio D, Colonna-Romano G, Di Bona D, Candore G, Caruso C (2009) Inflammation, ageing and cancer. Mech Ageing Dev 130, 40-45
45. Di Bona D, Candore G, Franceschi C, Licastro F, Colonna-Romano G, Camm̀a C, Lio D, Caruso C (2009) Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease. Brain Res Rev 61, 60-68.
46. Attia J, Ioannidis JP, Thakkinstian A, McEvoy M, Scott RJ, Minelli C, Thompson J, Infante-Rivard C, Guyatt G (2009) How to use an article about genetic association: A: Background concepts. JAMA 301, 74-81.
47. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, Ioannidis JP, Hirschhorn JN (2008) Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 9, 356-369.
48. http://www.alzforum.org/res/com/gen/alzgene/largescale.asp; accessed June 8, 2009
49. Bird TD (2005) Genetic factors in Alzheimer's disease. N Engl J Med 352, 862-864.
50. Candore G, Balistreri CR, Caruso M, Grimaldi MP, Incalcaterra E, List̀i F, Vasto S, Caruso C (2007) Pharmacogenomics: A tool to prevent and cure coronary heart disease. Curr Pharm Des 13, 3726-3734.
51. Candore G, Balistreri CR, Grimaldi MP, List̀i F, Vasto S. Chiappelli M, Licastro F, Colonna-Romano G, Lio D, Caruso C (2007) Polymorphisms of pro-inflammatory genes and Alzheimer's disease risk: A pharmacogenomic approach. Mech Ageing Dev 128, 67-75.